Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Zinc fingers to touch Gilead therapies
by Ryan Cross
March 5, 2018
| A version of this story appeared in
Volume 96, Issue 10
Gilead Sciences is betting big on gene editing to improve its cell immunotherapy programs. But rather than embrace CRISPR, Gilead has partnered with Sangamo Therapeutics, a pioneer of an older gene-editing tool called the zinc finger nuclease (ZFN). Sangamo has amassed a large ZFN protein library, allowing it to link ZFNs together to target any site in the genome. Gilead will give Sangamo $150 million up front and up to $3 billion more if Gilead develops 10 or more new therapies.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter